Transgenic mice expressing soluble Siglec-9 showed resistance against GBS.
Soluble Siglec-9 bound to GBS strains from serotypes Ia, Ib, II, III, IV and V.
Transgenic mice expressing soluble Siglec-9 eliminated GBS more efficiently.
Soluble Siglec-9 had an antibacterial benefit against GBS serotype III infection.